Johnson & Johnson, Pacira ink strategic co-promotion agreement

Johnson & Johnson, Pacira to expand osteoarthritis treatment options

Osteoarthritis is a degenerative condition impacting more than 30 million adults in the US. This collaboration will focus on the promotion of Zilretta (triamcinolone acetonide extended-release injectable suspension), The post Johnson & Johnson, Pacira partner to expand osteoarthritis treatment options appeared first on Pharmaceutical Business review.

Johnson & Johnson, Pacira ink strategic co-promotion agreement

Johnson & Johnson MedTech (NYSE:JNJ) today announced a strategic co-promotion agreement with Pacira BioSciences. The agreement expands the J&J MedTech Early Intervention portfolio with Pacira’s Zilretta. Zilretta (triamcinolone acetonide extended-release injectable suspension) is an extended-release injectable for the treatment of pain related to osteoarthritis (OA) of the knee. Zilretta first received FDA approval in October 2017 as the first a…